Adverse Outcomes Up With Kidney Retransplant in HIV+

This article originally appeared here.
Share this content:
Adverse Outcomes Up With Kidney Retransplant in HIV+
Adverse Outcomes Up With Kidney Retransplant in HIV+

THURSDAY, June 23, 2016 (HealthDay News) -- Primary HIV+ kidney transplant recipients who lose their graft and seek retransplantation (re-KT) have an increased risk of death and graft loss, according to a study published online June 15 in the American Journal of Transplantation.

Brittany A. Shelton, M.P.H., from the University of Alabama at Birmingham Comprehensive Transplant Institute, and colleagues studied the risk of death and graft loss among 4,149 (22 HIV+ and 4,127 HIV−) adult re-KT recipients.

The researchers found that HIV+ re-KT patients were more often African-American, infected with hepatitis C, and had longer median time on dialysis, compared with HIV− re-KT patients. The length of time between the primary and re-KT events did not differ significantly based on HIV status (1.5 and 1.4 years for HIV+ and HIV−, respectively; P = 0.52). Compared with HIV− re-KT recipients, HIV+ re-KT recipients had an elevated risk of death and graft loss (adjusted hazard ratios, 3.11 and 1.96, respectively).

"Re-KT among HIV+ recipients was associated with increased risk for mortality and graft loss," the authors write. "Future research is needed to determine if a survival benefit is achieved with re-KT in this vulnerable population."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths